Prof. ŞERİF ŞENTÜRK

Publication Network

Articles 51

1. Modeling hepatic fibrosis in TP53 knockout iPSC-derived human liver organoids

Karabicici M., Akbari S., Caliskan C., Celiker C., Oz O., Binokay L., et al.

MOLECULAR ONCOLOGY , 2025 (SCI-Expanded, Scopus) Sustainable Development

2. Escape from TGF-β-induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells

Kalyoncu M., Demirci D., Eris S., Dayanc B., Cakiroglu E., Basol M., et al.

MOLECULAR ONCOLOGY , vol.19, no.9, pp.2594-2618, 2025 (SCI-Expanded, Scopus) Sustainable Development

3. Integrative Network-Based Characterization of Serum Biomarker Interactions in Prostate Cancer Progression

ERBAK YILMAZ H., özel z., DİNÇKAL Ç., Karalar O., GÜÇ Z. G., DİNÇKAL M., et al.

Current Journal of Medical Research , vol.5, no.2, 2025 (Peer-Reviewed Journal)

4. Kemoterapi dirençli over kanseri hücrelerinde VPS28 geninin CRISPR- Cas9 yöntemi ile susturulmasının cisplatin yanıtı üzerine etkileri

GÜLER KARA H., DOĞAN E., BOZOK V., ŞENTÜRK Ş., KOSOVA B.

Mersin Üniversitesi Sağlık Bilimleri Dergisi , vol.18, no.2, 2025 (TRDizin)

5. Modelling neuroendocrine differentiation in bladder cancer and analysis of phenotypic and molecular effects

Boyvath E., Akman B., YÖRÜKOĞLU K., Atabey N., ŞENTÜRK Ş., ERKEK ÖZHAN S.

FEBS OPEN BIO , vol.15, pp.220, 2025 (SCI-Expanded, Scopus) Sustainable Development

6. The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

Guler Kara H., Dogan E., Bozok V., Aktan C., Cakiroglu E., Eroglu Z., et al.

FEBS JOURNAL , vol.292, no.14, pp.3755-3770, 2025 (SCI-Expanded, Scopus) Sustainable Development

7. Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer

Dayanc B., Eris S., Gulfirat N. E., Ozden-Yilmaz G., Cakiroglu E., Coskun Deniz O. S., et al.

CELL DEATH & DISEASE , vol.16, no.1, 2025 (SCI-Expanded, Scopus) Sustainable Development

8. Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma

Cakiroglu E., Eris S., Oz O., Karakülah G., Senturk Ş.

CELL DEATH & DISEASE , vol.16, no.1, 2025 (SCI-Expanded, Scopus) Sustainable Development

9. Leveraging Circular Polymerization and Extension Cloning (CPEC) Method for Construction of CRISPR Screening Libraries

Dayanç B., ERİŞ S., ŞENTÜRK Ş.

BIO-PROTOCOL , vol.15, no.4, 2025 (ESCI, Scopus) Sustainable Development

10. Hepatic fibrogenesis in TP53KO organoids within a pro-carcinogenic microenvironment

Karabicici M., Akbari S., ÇALIŞKAN C., KARAKÜLAH G., ŞENTÜRK Ş., ÖZ Ö., et al.

FEBS OPEN BIO , vol.14, pp.306, 2024 (SCI-Expanded)

11. **Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells**

Ozgun G., Yaras T., Akman B., Özden-Yılmaz G., Landman N., Karakülah G., et al.

CANCER GENE THERAPY , vol.31, no.4, pp.537-551, 2024 (SCI-Expanded, Scopus) Sustainable Development

12. CRISPR/Cas9 Therapy in Cancer Treatment

Cakiroglu E., ŞENTÜRK Ş.

INNOVATIVE APPROACHES IN CANCER DIAGNOSIS AND TREATMENT , pp.44-52, 2024 (SCI-Expanded)

13. Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders

Şentürk Ş., Akbaba H., Erel Akbaba G., Başpınar Y.

ACS OMEGA , vol.8, no.48, pp.46101-46112, 2023 (SCI-Expanded, Scopus) Sustainable Development

14. Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by Pichia pastoris

Kalyoncu S., Yilmaz S., Kuyucu A. Z., Sayili D., Mert O., Soyturk H., et al.

SCIENTIFIC REPORTS , vol.13, no.1, 2023 (SCI-Expanded, Scopus)

15. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer

Atalay E. B., Senturk Ş., Kayali H.

BIOCHEMICAL GENETICS , vol.61, no.4, pp.1470-1486, 2023 (SCI-Expanded, Scopus) Sustainable Development

16. Osimertinib resistance mechanisms in nonsmall cell lung cancer using focused CRISPR Screen: FOSL1 and JUN

Uluata-Dayanc B., ERİŞ S., Cakiroglu E., Ozden-Yilmaz G., Coskun-Deniz O. S., KARAKÜLAH G., et al.

FEBS OPEN BIO , vol.13, pp.149-150, 2023 (SCI-Expanded)

17. MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth

Şentürk Ş.

LIFE SCIENCES , vol.323, 2023 (SCI-Expanded, Scopus) Sustainable Development

18. The paracaspase MALT1 is a downstream target of Smad3 and potentiates the crosstalk between TGF-β and NF-kB signaling pathways in cancer cells

Mazi F. A., Cakiroglu E., Uysal M., Kalyoncu M., Demirci D., Sozeri P. Y. G., et al.

CELLULAR SIGNALLING , vol.105, 2023 (SCI-Expanded, Scopus) Sustainable Development

19. Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines

Özden-Yılmaz G., Savas B., Bursalı A., Eray A., Arıbaş A., ŞENTÜRK Ş., et al.

CELLS , vol.12, no.6, 2023 (SCI-Expanded, Scopus) Sustainable Development

20. FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer

Guneri-Sozeri P. Y., Özden-Yılmaz G., Kisim A., Cakiroglu E., Eray A., Uzuner H., et al.

COMMUNICATIONS BIOLOGY , vol.6, no.1, 2023 (SCI-Expanded, Scopus)

21. CRISPR-Cas Functional Genetic Screening: Traditional Review

GÜLER KARA H., KOSOVA B., DOĞAN E., BOZOK ÇETİNTAŞ V., ŞENTÜRK Ş.

Türkiye Klinikleri Tıp Bilimleri Dergisi , vol.42, no.4, pp.311-322, 2022 (Scopus, TRDizin)

22. Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen

Dayanc B. U., Eris S., Cakiroglu E., Mazi F. A., COŞKUN BADUR S., Demirci D., et al.

JOURNAL OF THORACIC ONCOLOGY , vol.17, no.9, 2022 (SCI-Expanded, Scopus)

23. Genome-wide CRISPR screen identifies BUB1 as a cancer-dependency gene in malignant pleural mesothelioma

Cakiroglu E., ŞENTÜRK Ş., KARAKÜLAH G.

FEBS OPEN BIO , pp.18, 2022 (SCI-Expanded, Scopus) Sustainable Development

24. Engineering and validation of a dual luciferase reporter system for quantitative and systematic assessment of regulatory sequences in Chinese hamster ovary cells.

Toktay Y., Dayanc B., Senturk Ş.

Scientific reports , vol.12, no.1, pp.6050, 2022 (SCI-Expanded, Scopus)

25. The Bright and the Dark Side of TGF-beta Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications

Gungor M. Z., Uysal M., Şentürk Ş.

CANCERS , vol.14, no.4, 2022 (SCI-Expanded) Sustainable Development

26. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization

Batur T., Argundogan A., Keles U., Mutlu Z., Alotaibi H., Senturk Ş., et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , vol.22, no.24, 2021 (SCI-Expanded) Sustainable Development

27. Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines

Gungor M. Z., Uysal M., Ozturk M., Şentürk Ş.

JOURNAL OF GASTROINTESTINAL CANCER , vol.52, no.4, pp.1320-1335, 2021 (Scopus) Sustainable Development

28. Changes in Wnt and TGF-beta Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7

Karabicici M., Azbazdar Y., Ozhan G., Şentürk Ş., Firtina Karagonlar Z., Erdal E.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY , vol.09, 2021 (SCI-Expanded, Scopus) Sustainable Development

29. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression

Tepes P. S., Pal D., Lindsted T., Ibarra I., Lujambio A., Sabinina V. J., et al.

ELIFE , vol.10, 2021 (SCI-Expanded, Scopus) Sustainable Development

30. Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond

Ozgun G., ŞENTÜRK Ş., Erkek-Ozhan S.

INTERNATIONAL JOURNAL OF CANCER , vol.148, no.10, pp.2364-2374, 2021 (SCI-Expanded, Scopus) Sustainable Development

31. Identification of Essential Genes in Malignant Pleural Mesothelioma Using Genome-Wide CRISPR/Cas9-Based Negative Selection Screen

Cakiroglu E., Coskun O., Karakulah G., Senturk Ş.

JOURNAL OF THORACIC ONCOLOGY , no.3, 2021 (SCI-Expanded, Scopus)

32. The Jekyll and Hyde of Cellular Senescence in Cancer

Demirci D., Dayanc B., Mazi F. A., Şentürk Ş.

CELLS , vol.10, no.2, 2021 (SCI-Expanded)

33. Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing

AKBABA H., EREL AKBABA G., ŞENTÜRK Ş.

NANOMEDICINE , vol.16, no.12, pp.963-978, 2021 (SCI-Expanded, Scopus)

34. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Klionsky D. J., Abdel-Aziz A. K., Abdelfatah S., Abdellatif M., Abdoli A., Abel S., et al.

Autophagy , vol.17, no.1, pp.1-382, 2021 (SCI-Expanded) Sustainable Development

35. Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Cakiroglu E., Şentürk Ş.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , vol.21, no.17, 2020 (SCI-Expanded) Sustainable Development

36. Next-Generation Liver Medicine Using Organoid Models

Akbari S., Arslan N., Şentürk Ş., Erdal E.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY , vol.7, 2019 (SCI-Expanded)

37. Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma

Gunes A., Bagirsakci E., İŞCAN E., ÇAKAN AKDOĞAN G., aykutlu u., ŞENTÜRK Ş., et al.

Oncotarget , vol.9, no.96, 2018 (Scopus)

38. Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes

Sachan N., Miller M., Shirole N. H., ŞENTÜRK Ş., Corbo V., Kinney J. B., et al.

GENOME EDITING AND ENGINEERING: FROM TALENS, ZFNS AND CRISPRS TO MOLECULAR SURGERY , pp.337-357, 2018 (SCI-Expanded) Sustainable Development

39. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization

ŞENTÜRK Ş., Shirole N. H., Nowak D. G., Corbo V., Pal D., Vaughan A., et al.

NATURE COMMUNICATIONS , vol.8, pp.1-10, 2017 (SCI-Expanded, Scopus)

40. TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions

Shirole N. H., Pal D., Kastenhuber E. R., ŞENTÜRK Ş., Boroda J., Pisterzi P., et al.

ELIFE , vol.5, 2016 (SCI-Expanded, Scopus) Sustainable Development

41. A rapid and tunable method to temporally control Cas9 expression enables the identification of essential genes and the interrogation of functional gene interactions in vitro and in vivo

ŞENTÜRK Ş., Shirole N., Nowak D., Corbo V., Vaughan A., Tuveson D., et al.

BioRxiv , 2015 (Peer-Reviewed Journal)

42. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2

Nowak D. G., Cho H., Herzka T., Watrud K., DeMarco D. V., Wang V. M. Y., et al.

CANCER DISCOVERY , vol.5, no.6, pp.636-651, 2015 (SCI-Expanded, Scopus) Sustainable Development

43. p53 Psi is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state

ŞENTÜRK Ş., Yao Z., Camiolo M., Stiles B., Rathod T., Walsh A. M., et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , vol.111, no.32, 2014 (SCI-Expanded, Scopus)

44. Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton

Mender I., ŞENTÜRK Ş., Ozgunes N., Akcali K. C., Kletsas D., Gryaznov S., et al.

INTERNATIONAL JOURNAL OF ONCOLOGY , vol.42, no.5, pp.1709-1715, 2013 (SCI-Expanded, Scopus) Sustainable Development

45. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status

Buontempo F., Ersahin T., Missiroli S., ŞENTÜRK Ş., Etro D., Ozturk M., et al.

INVESTIGATIONAL NEW DRUGS , vol.29, no.6, pp.1303-1313, 2011 (SCI-Expanded, Scopus) Sustainable Development

46. Dose- and time-dependent expression patterns of zebrafish orthologs of selected E2F target genes in response to serum starvation/replenishment

Sucularli C., ŞENTÜRK Ş., Ozturk M., KONU KARAKAYALI Ö.

MOLECULAR BIOLOGY REPORTS , vol.38, no.6, pp.4111-4123, 2011 (SCI-Expanded, Scopus) Sustainable Development

47. Transforming Growth Factor-Beta Induces Senescence in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth

ŞENTÜRK Ş., Mumcuoglu M., Gursoy-Yuzugullu O., Cingoz B., Akcali K. C., Ozturk M.

HEPATOLOGY , vol.52, no.3, pp.966-974, 2010 (SCI-Expanded, Scopus) Sustainable Development

48. The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast Cancer Cell Heterogeneity

Mumcuoglu M., Bagislar S., Yuzugullu H., Alotaibi H., Şentürk Ş., Telkoparan P., et al.

PLOS ONE , vol.5, no.6, 2010 (SCI-Expanded, Scopus)

49. Senescence and immortality in hepatocellular carcinoma

Ozturk M., ARSLAN ERGÜL A., Bagislar S., ŞENTÜRK Ş., Yuzugullu H.

CANCER LETTERS , vol.286, no.1, pp.103-113, 2009 (SCI-Expanded, Scopus) Sustainable Development

50. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells

Yuzugullu H., Benhaj K., Ozturk N., ŞENTÜRK Ş., Celik E., Toylu A., et al.

MOLECULAR CANCER , vol.8, 2009 (SCI-Expanded, Scopus)

51. Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells

Ozturk N., Erdal E., Mumcuoglu M., Akcali K. C., Yalcin O., ŞENTÜRK Ş., et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , vol.103, no.7, pp.2178-2183, 2006 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 82

1. Protein truncating mutation occurring in C-terminus of FYR domain of Kabuki Syndrome-Associated KMT2D gene causes major changes in chromatin organization

Özden Yılmaz G., Ölmez Türker A., Yılmazbilek İ., KARAKÜLAH G., OKTAY Y., GENÇPINAR P., et al.

17th Annual ICORD Meeting, 14 November 2025, (Summary Text)

2. Generation of Retinohypothalamic Tract Model Using Retina-Hypothalamus Assembloid Model for Circadian Rhythm Analysis

Kahveci B., ÇAKIROĞLU E., ŞENTÜRK Ş., KAVAKLI İ. H., GÜVEN S.

9th International Congress of the Molecular Biology Association of Turkey, İzmir, Turkey, 12 - 14 September 2024, (Summary Text)

3. Investigation of the Effects of Mutations in the FYR Module of Kabuki Syndrome-Associated KMT2D Gene on Protein Interactions and Chromatin Organization

Özden Yılmaz G., Yılmazbilek İ., Ölmez Türker A., Ozkan Kucuk N. E., ÖZLÜ SICAKKAN N., KARAKÜLAH G., et al.

9th International Congress of the Molecular Biology Association of Turkey, İzmir, Turkey, 12 - 14 September 2024, (Summary Text)

4. EGF Promotes Neuroendocrine-Like Differentiation of Bladder Cancer

BOYVATLI E., Akman B., YÖRÜKOĞLU K., ATABEY S. N., ŞENTÜRK Ş., ERKEK ÖZHAN S.

9th International Congress of the Molecular Biology Association of Turkey, İzmir, Turkey, 12 - 14 September 2024, (Summary Text)

5. Escape from TGF-β-induced Senescence Promotes Aggressive Cancer Hallmarks in Epithelial Hepatocellular Carcinoma Cells

Kalyoncu M., Demirci D., ERİŞ S., Uluata Dayanç B., ÇAKIROĞLU E., BAŞOL M., et al.

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.347-348, (Summary Text) Sustainable Development

6. Genome-wide CRISPR Screening Identifies RUVBL1/2 Complex as a Druggable Vulnerability in Bladder Cancer

AKDEMİR B., ERİŞ S., Kalyoncu M., ÇAKIROĞLU E., Coşkun Ö. Ş., KARAKÜLAH G., et al.

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.180-181, (Summary Text) Sustainable Development

7. Pooled CRISPR Screening Identifies AP-1 Transcription Factor as a Druggable Driver of Osimertinib Resistance in Non-Small Cell Lung Cancer

ULUATA DAYANÇ B., ERİŞ S., ÇAKIROĞLU E., Özden Yılmaz G., Gülfırat N. E., Coşkun Ö. Ş., et al.

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.224, (Summary Text) Sustainable Development

8. Genome-Wide CRISPR Screens: Unveiling BUB1 Kinase as a Druggable Vulnerability in Malignant Pleural Mesothelioma

ÇAKIROĞLU E., ERİŞ S., Öz Ö., KARAKÜLAH G., ŞENTÜRK Ş.

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.183-184, (Summary Text)

9. EGF promotes neuroendocrine-like differentiation of bladder cancer

Akman B., Boyvatlı E., Yörükoğlu K., Şentürk Ş., Erkek Özhan S.

16. Üroonkoloji Kongresi, Antalya, Turkey, 8 - 12 November 2023, pp.291, (Full Text) Sustainable Development

10. A molecular portrait of retinoids and EZH2 inhibitors cooperation to orchestrate cytotoxic effects on bladder cancer cells

Özgün G., Yaraş T., Landman N., KARAKÜLAH G., van Lohuizen M., ŞENTÜRK Ş., et al.

The 47th FEBS Congress, 8 - 12 July 2023, vol.13, (Summary Text)

11. Structural dynamics of the intrinsically disordered SNARE protein SNAP25a in its pre-fusion conformation

Stief T., Vormann K., Gremer L., Biehl R., ŞENTÜRK Ş., Lakomek N.

14th European Biophysics Congress (EBSA), Stockholm, Sweden, 31 July - 04 August 2023, vol.52, (Summary Text)

12. The Molecular Role of RUVBL1 Gene on Cancer Cell Phenotypes in Malignant Pleural Mesothelioma

Güngör M. Z., Çakıroğlu E., Akdemir B., Şentürk Ş.

The International Biochemistry Congress & 33rd National Biochemistry Congress, İzmir, Turkey, 26 - 30 October 2022, (Summary Text) Sustainable Development

13. ATG9A Gene is Required for the Survival of Malignant Pleural Mesthelioma Cells

Uysal M., Çakıroğlu E., Tutcu Ö., Mutlu Ö., Şentürk Ş.

The International Biochemistry Congress & 33rd National Biochemistry Congress, İzmir, Turkey, 26 - 30 October 2022, pp.1-5, (Summary Text) Sustainable Development

14. Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen

Dayanç B., Eriş S., Çakıroğlu E., Mazı F. A., Coşkun Ö. Ş., Demirci D., et al.

IASLC 2022 WCLC World Conference on Lung Cancer, Vienna, Austria, 6 - 09 August 2022, vol.17, pp.407, (Summary Text) Sustainable Development

15. Genome-wide CRISPR screen identifies BUB1 as a cancer-dependency gene in malignant pleural mesothelioma

Cakiroglu E., Şentürk Ş., Karakülah G.

IUBMB-FEBS-PABMB 2022 Congress, Lisbon, Portugal, 9 - 14 July 2022, vol.12, pp.18, (Summary Text) Sustainable Development

16. AXL is essential for survival of mesenchymal-like HCC cells

Batur T., Argundogan A., Mutlu Z., KELEŞ U., ALOTAİBİ H., ŞENTÜRK Ş., et al.

8th International Congress of the Molecular Biology Association of Turkey, İstanbul, Turkey, 9 - 12 June 2022, (Summary Text)

17. The Role of Autophagy on Differentiation of Corneal Endothelial Cells from hiPSCs

KOÇAK G., Cakiroglu E., YILDIRIM C. A., ŞENTÜRK Ş., GÜVEN S.

8th International Congress of the Molecular Biology Association of Turkey, İstanbul, Turkey, 9 - 12 June 2022, (Summary Text)

18. Targeted delivery of CRISPR/Cas9 plasmid system for cancer immunotherapy approaches

AKBABA H., Özder M., EREL AKBABA G., ŞENTÜRK Ş.

13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Amsterdam, Netherlands, 28 - 31 March 2022, (Full Text)

19. CRISPR-CAS9 Teknolojisi ile in vitro F8 Geninin Fonksiyonunun Bozulmasının Sağlanması

Shekari M., GÜNDÜZ C., ATİK T., YILMAZ SÜSLÜER S., ŞENTÜRK Ş., IŞIK E., et al.

8. Hemofili Vakalarla Eğitim Sempozyumu, 18 - 20 February 2022, (Summary Text)

20. Küçük Hücreli Dışı Akciğer Kanserinde Genetik Olmayan Osimertinib Direnç Mekanizmalarının CRISPR Tarama Aracılı Araştırılması

Uluata Dayanç B., Eriş S., Çakıroğlu E., Mazı F. A., Coşkun Ö. Ş., Demirci D., et al.

XVII. Tıbbi Biyoloji ve Genetik Kongresi, İzmir, Turkey, 28 - 31 October 2021, (Summary Text) Sustainable Development

21. Generation of R132H point mutation by CRISPR/Cas9 method in colorectal cancer cell line

BULUT ATALAY E., ŞENTÜRK Ş., AYAR KAYALI H.

3. Uluslararası Kanser ve İyon Kanalları Kongresi (CANCERION-2021), 16 September 2021, (Summary Text) Sustainable Development

22. Generation of R132H point mutation by CRISPR/Cas9 method in colon cancer cell line

BULUT ATALAY E., ŞENTÜRK Ş., AYAR KAYALI H.

3. Uluslararası Kanser ve İyon Kanalları Kongresi, İstanbul, Turkey, 16 - 18 September 2021, (Summary Text) Sustainable Development

23. Generation of cell models using CRISPR/Cas9-based gene therapy to study molecular functions of IDH in colorectal cancer

BULUT ATALAY E., Çakıroğlu E., ŞENTÜRK Ş., AYAR KAYALI H.

BioTürkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 9 - 11 September 2021, (Full Text) Sustainable Development

24. Revealing the Role of Retinoids On the Phenotypic and Epigenetic Landscape of Bladder Cancer Cells

Özgün G., ŞENTÜRK Ş., ERKEK ÖZHAN S.

6. Uluslararası Tıp ve Sağlık Bilimleri Araştırmaları Kongresi, Ankara, Turkey, 10 - 11 April 2021, (Summary Text) Sustainable Development

25. P62.02 Identification of Essential Genes in Malignant Pleural Mesothelioma Using Genome-Wide CRISPR/Cas9-Based Negative Selection Screen

Çakıroğlu E., Coşkun Ö. Ş., KARAKÜLAH G., ŞENTÜRK Ş.

IASLC 2020 World Conference on Lung Cancer, Singapore, 28 - 31 January 2021, vol.16, pp.548, (Summary Text)

26. Gen Düzeltme ve CRISPR

ŞENTÜRK Ş.

Türk Toraks Derneği 23. Yıllık Kongresi, Turkey, 15 - 18 October 2020, (Summary Text)

27. Genç Araştırmacılar İçin Fırsatlar

ŞENTÜRK Ş.

BioTürkiye - Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 5 - 07 March 2020, (Summary Text)

28. A Novel Concept for Immune Checkpoint Gene Knockout Via Lipid Based Non-Viral Delivery Systems

AKBABA H., Özder M., EREL AKBABA G., ŞENTÜRK Ş.

Bio Turkey International Biotechnology Congress, İstanbul, Turkey, 5 - 07 March 2020, (Summary Text)

29. CRISPR-Cas9 Genom Düzenleme

ŞENTÜRK Ş.

22. EGE Onkoloji Günleri-Onkolojide Yeni Tedavi Arayışları Sempozyumu, Turkey, 26 - 28 February 2020, (Summary Text)

30. Genome-wide CRISPR-Cas9 screening for the identification of cancer essential genes in malignant pleural mesothelioma

Çakıroğlu E., Coşkun Ö. Ş., ŞENTÜRK Ş.

27th Balkan Clinical Laboratory Federation Congress and 30th National Biochemistry Congress, Turkey, 27 - 31 October 2019, vol.44, (Summary Text) Sustainable Development

31. HEPATOSELÜLER KARSİNOMADA YENİ YAKLAŞIM: POTANSİYEL İLAÇ HEDEFİ OLARAK AXL RESEPTÖRÜ

Batur T., KELEŞ U., İŞCAN E., Öz Ö., ŞENTÜRK Ş., ÇAKAN AKDOĞAN G., et al.

Onkolojide İz Bırakanlar, Antalya, Turkey, 14 - 17 November 2019, (Summary Text)

32. Malign plevral mezotelyoma tümörigenez mekanizmalarının CRISPR-Cas9 tarama ile araştırılması

Çakıroğlu E., Coşkun Ö. Ş., Kurden Pekmezci A., ŞENTÜRK Ş.

Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019, (Summary Text)

33. TGF-β’ya bağlı kanser hücre sekretomunun regülasyonunda Malt1’ın rolü

MAZI F. A., Çakıroğlu E., Kurden Pekmezci A., Demirci D., ŞENTÜRK Ş.

Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019, (Summary Text) Sustainable Development

34. HEPATOSELLÜLER KARSİNOMDA TGF-Β YANITININ HÜCRESEL MEKANİZMALARININ ARAŞTIRILMASI

DEMİRCİ D., ECE Ç., BENGİSU U. D., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.

ONKOLOJİDE İZ BIRAKANLAR ZİRVESİ, Turkey, 14 - 17 November 2019, (Summary Text)

35. İnvazin olan ve invaziv olmayan mesane kanseri hücre hatlarını karakterize eden transkripsiyonel düzenleyici ağların tanımlanması

Güneri P. Y., Özden Yılmaz G., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.

Onkolojide İz Bırakanlar Zirvesi, Turkey, 14 - 17 November 2019, (Summary Text) Sustainable Development

36. Hepatoselüler karsinom hücre hatlarında Malt1 tükenmesinin büyüme baskılayıcı etkilerinin araştırılması

Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., Demirci D., ŞENTÜRK Ş.

Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019, (Summary Text)

37. Hepatosellüler Karsinoma’da AXL’ın rolü

Batur T., KELEŞ U., ŞENTÜRK Ş., ÇAKAN AKDOĞAN G., mutlu Z., İŞCAN E., et al.

16.Tıbbi Biyolojie ve Genetik Kongresi, 27 - 30 October 2019

38. Identification of transcriptional regulatory networks characterizing invasive and non-invasive bladder cancer cell lines.

Güneri P. Y., Özden Yılmaz G., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.

The International Symposium on Health Informatics and Bioinformatics, 17 - 19 October 2019, (Summary Text) Sustainable Development

39. Identification of transcriptional regulatory networks characterizing invasive and non-invasive bladder cancer cell lines

Güneri P. Y., Yılmaz G. Ö., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.

17th Meeting of the International Bladder Cancer Network, 3 - 05 October 2019 Sustainable Development

40. Malt1 Paracaspase Inhibition Reduces Hepatocellular Carcinoma Cell Survival

Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., Demirci D., ŞENTÜRK Ş.

1st INTERNATIONAL MULTIDISCIPLINARY CANCER RESEARCH CONGRESS, 18 - 22 September 2019, (Summary Text)

41. Investigation of the role of Malt1 Paracaspase in Hepatocellular Carcinoma Cell Survival

Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., ŞENTÜRK Ş.

3. Çukurova Hepatoselüler Karsinoma Kongresi, Adana, Turkey, 21 - 23 February 2019, (Summary Text)

42. Investigation of cellular mechanisms of TGF-beta resistance in hepatocellular carcinoma

Demirci D., Çakıroğlu E., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.

3. Çukurova Hepatoselüler Karsinoma Kongresi, Adana, Turkey, 21 - 23 February 2019

43. Kanser Esansiyel Genlerin Tüm Genom CRISPR-Cas9 Taramalarla Araştırılması

ŞENTÜRK Ş.

İmmünolojide Moleküller Sempozyumu, Turkey, 18 - 21 October 2018, (Summary Text) Sustainable Development

44. Engineering and Functional Validation of Clonal Cell Lines with Stable Cas9 Expression for Genome-Wide CRISPR Screen in Malignant Pleural Mesothelioma

Çakıroğlu E., Dumral Ö., Coşkun Ö. Ş., ŞENTÜRK Ş.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018

45. Systematic Comparison of Constitutive Promoters in Chinese Hamster Ovary Cells

Toktay Y., Zeybek Kuyucu A., Gürkan Y., ŞENTÜRK Ş.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018

46. Investigation of the Cellular Mechanisms of TGF--induced Senescence-Resistance in Hepatocellular Carcinoma

Demirci D., Çakıroğlu E., Bingöl B., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018

47. The Role of Malt1 Paracaspase in Hepatocellular Carcinoma

Kurden Pekmezci A., Çakıroğlu E., ŞENTÜRK Ş.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018

48. AXL as a Potential Target in Liver Cancer

Batur T., KELEŞ U., İŞCAN E., ŞENTÜRK Ş., ÖZTÜRK M.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018, (Summary Text) Sustainable Development

49. THE NEW FRONTIER OF GENOME ENGINEERING: THE CRISPR/CAS9 SYSTEM

ŞENTÜRK Ş.

The Second International Biomedical Engineering Congress, 24 - 27 May 2018, (Summary Text)

50. Genom Mühendisliği ve CRISPR-Cas Devrimi

ŞENTÜRK Ş.

14. Ulusal Histoloji ve Embriyoloji Kongresi, Turkey, 10 - 13 May 2018

51. TXNIP’xxin HCC gelişimi ve ilerleyişindeki rolü

Güneş A., İŞCAN E., Bağırsakçı E., ÇAKAN AKDOĞAN G., aykutlu u., ŞENTÜRK Ş., et al.

XV.Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Turkey, 26 - 29 October 2017, (Summary Text)

52. Biyobelirteçler ve CRISPR

ŞENTÜRK Ş.

II. Türkiye in vitro Diyagnostik (IVD) Sempozyumu, Turkey, 10 - 12 May 2017, (Summary Text)

53. CRISPR/Cas9 İşlevsel Genomik Tarama ve Rekabet Tayini ile Kanser EsansiyelGenlerin Keşfi ve in Vitro Karakterizasyonu

ŞENTÜRK Ş.

1. Çukurova Hepatoselüler Karsinoma Sempozyumu, Turkey, 10 - 12 February 2017, (Summary Text) Sustainable Development

54. In Vitro and In Vivo Characterization Of Cell Survival Genes Using Destabilized Cas9

ŞENTÜRK Ş.

1st International Cell Death Research Congress, İzmir, Turkey, 4 - 07 May 2016, (Summary Text)

55. Role of MCPIP1 in Tumor Microenvironment

Sachan N., ŞENTÜRK Ş., Raffaella S.

2016 CSHL Annual Symposium, 21 - 22 November 2016, (Summary Text)

56. TP53 Truncating Alleles in Tumor Progression

Shirole N., Pal D., ŞENTÜRK Ş., Sordella R.

CSHL Annual Symposium, 21 - 22 November 2016, (Summary Text)

57. Truncating Alleles in TP53 Produce Separation of Function Mutants That Actively Promote Tumorigenesis

Shirole N., Pal D., Kastenhuber E., ŞENTÜRK Ş., Pisterzi P., Boroda J., et al.

81st Cold Spring Harbor Laboratory Symposium on Quantitative Biology, 1 - 05 June 2016, (Summary Text)

58. A rapid and tunable method to temporally control Cas9expression enables the characterization of essential genes andthe interrogation of functional gene interactions in vitro and invivo

ŞENTÜRK Ş., Shirole N., Nowak D. G., Corbo V., Tuveson D. A., Trotman L. C., et al.

Genome Engineering: The CRISPR/CAS Revolution, 24 - 27 September 2015, (Summary Text)

59. Myc drives Pten p53 deficient proliferation and metastasis due to Il6 secretion and Akt suppression via Phlpp2

Nowak D. G., Cho H., Herzka T., Wang V. M., ŞENTÜRK Ş., DeMarco D. V., et al.

AACR Annual Meeting, 18 - 22 April 2015, (Summary Text)

60. Myc drives Pten/ p53-deficient proliferation and metastasis due to Il6-secretion and Akt-suppression via Phlpp2

Nowak D. G., Cho H., Herzka T., Wang V. M. Y., ŞENTÜRK Ş., DeMarco D. V., et al.

106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Pennsylvania, United States Of America, 18 - 22 April 2015, vol.75, (Summary Text)

61. Does Akt Inactivation promote metastasis of PTEN mutant cancer

Dawid N., Cho H., Herzka T., Wang V., ŞENTÜRK Ş., Demarco D., et al.

Biology of Cancer: Microenvironment, Metastasis & Therapeutics, 12 - 16 May 2015, (Summary Text) Sustainable Development

62. Functional characterization of genomic abnormalities that cooperate with EGFR and K Ras oncogenic mutations in lung cancer

ŞENTÜRK Ş., Shirole N., Camiolo M., Van Aelst L., Lowe S., Sander C., et al.

Starr Cancer Consortium, 11 - 12 May 2015, (Full Text) Sustainable Development

63. Substrate specificity of receptor tyrosine kinases is critical for selective signaling and addiction

PİNEDA M., YAO Z., PUZIS L., ŞENTÜRK Ş., SORDELLA R.

Protein Phosphorylation, Cellular Plasticity and Signaling Rewiring, FASEB Meeting, 20 - 25 July 2014, (Full Text)

64. p53 is a neomorphic p53 isoform that reprograms cells towards the acquisition of metastatic features despite lacking transcriptional activity

CAMİOLO M., YAO Z., ŞENTÜRK Ş., LİNDSTED T., KRAİNER A., LOWE S., et al.

Mechanisms & Models of Cancer Meeting, CSHL, 14 August - 18 April 2012, (Summary Text)

65. Substrate specifity of receptor tyrosine kinases is critical for selective signaling

PİNEDA M., YAO Z., LİNDSTED T., ŞENTÜRK Ş., SORDELLA R.

Mechanisms & Models of Cancer Meeting, CSHL, 14 - 18 August 2012, (Summary Text)

66. SOCS2 leads to EGFR TKi resistance in lung cancer by activating IL 6 mediated signaling

ŞENTÜRK Ş., TAŞ İ., YAO Z., FENOGLİO S., SORDELLA R.

Mechanisms & Models of Cancer Meeting, CSHL, 14 - 18 August 2012, (Summary Text) Sustainable Development

67. The Effects of Telomerase Inhibitor GRN163L Imetelstat On Cell Cytoskeleton and Cell Cycle

MENDER İ., ŞENTÜRK Ş., GRYAZNOV S., ÖZGÜNEŞ N., CAN A., DİKMEN Z. G.

21st Biochemistry Congress, İstanbul, Turkey, 28 - 31 October 2009, (Full Text)

68. TGF-BETA SIGNALING IS FUNCTIONAL, BUT ITS SENESCENCE RESPONSE IS DEFECTIVE IN POORLY DIFFERENTIATED HEPATOCELLULAR CARCINOMA CELL LINES

ŞENTÜRK Ş., Ozturk M.

60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 30 October - 03 November 2009, vol.50, (Summary Text)

69. Effect of Akt pathway inhibitors in HCC a novel target for treatment

ERŞAHİN T., BUONTEMPO F., ŞENTÜRK Ş., NERİ L., ATALAY R.

3rd ILCA Annual Conference, Milan, Italy, 4 - 06 September 2009, (Summary Text)

70. The Effects of Telomerase Inhibitor GRN163L on Different Cell Lines

MENDER İ., ŞENTÜRK Ş., DİKMEN Z. G., GRYAZNOV S., CAN A., ÖZGÜNEŞ N.

2nd FEBS Advanced Lecture Course on Matrix Pathobiology, Patras, Greece, 11 - 16 July 2009, (Full Text)

71. Downregulation and the anti growth effect of Zeb2 in hepatocellular carcinoma

ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., YÜZÜGÜLLÜ H., BOZDOĞAN Ö., et al.

Joint 4th EORTC Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009, (Summary Text)

72. TGF beta induces senescence in epithelial like hepatocellular carcinoma cells

ŞENTÜRK Ş., ÖZTÜRK M.

Joint 4th EORTC Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009, (Summary Text)

73. Molecular Mechanisms of TGF beta induced senescence in hepatocellular carcinoma

ŞENTÜRK Ş., ÖZTÜRK M.

20. ULUSAL BİYOKİMYA KONGRESİ, Turkey, 29 October - 01 November 2008, (Summary Text)

74. SMAD interacting protein 1 SIP 1 acts as a negative regulator of growth in hepatocellular carcinoma cells

ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., ÖZTÜRK M.

ILCA MEETING, 5 - 07 October 2007, (Summary Text)

75. TGF beta induces p53 Rb independent but oxidative stress dependent cellular senescence in hepatocellular carcinoma cells

ŞENTÜRK Ş., ERGÜL A., AKKIZ H., ÖZTÜRK M.

ILCA Meeting, 5 - 07 October 2007, (Summary Text)

76. Induction of senescence as a potential therapeutic strategy in hepatocellular carcinoma

ÖZTÜRK M., BAĞIŞLAR S., ŞENTÜRK Ş., ARSLAN ERGÜL A., ÖZTÜRK N.

International Meeting on Translational Worldwide Perspective for Liver Cancer, 9 - 10 July 2007, (Summary Text)

77. Role of SMAD interacting protein 1 in reprogramming of replicative senescence

ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., LAÇİN E., ÖZTÜRK M.

II. International Congress of Molecular Medicine, 24 - 28 March 2007, (Full Text)

78. Role of TGF beta and ROS signaling pathways in hepatocellular senescence

ŞENTÜRK Ş., ERGÜL A., ÖZTÜRK N., AKKIZ H., ÖZTÜRK M.

II. International Congress of Molecular Medicine, Istanbul, 24 - 28 March 2007, (Full Text)

79. TGF beta Signaling Pathway in Hepatocellular Senescence

ŞENTÜRK Ş., ÖZTÜRK M.

6th FEBS Young Scientists Forum, 22 - 24 June 2006, (Summary Text)

80. Induction of replicative senescence in hepatocellular carcinoma cells

Ozturk N., Erdal E., Mumcuoglu M., Akcali K. C., YALÇIN Ö. T., ŞENTÜRK Ş., et al.

31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.224-225, (Summary Text)

81. Role of TGF-beta signaling in hepatocellular senescence

ŞENTÜRK Ş., Arslan-Ergul A., Ozturk N., Akkiz H., Ozturk M.

31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.225, (Summary Text)

82. Characterization of TGF beta induced Early Senescence in Hepatocellular Carcinoma Cell Lines

ŞENTÜRK Ş., ÖZTÜRK M.

ICGEB Workshop Emerging Topics in Human Functional Genomics and Proteomics, 26 - 31 March 2006, (Summary Text)

Books 6

1. RUVBL1/2 Complex in Cancer: Emerging Mechanisms and Therapeutic Opportunities

Akdemir B., Güngör M. Z., Şentürk Ş.

in: Novel Therapeutic Targeting in Cancer: An Interdisciplinary Approach, Rezaei Nima, Editor, Springer, London/Berlin , London, pp.567-590, 2026

2. Structure and Function of the H19 Long Non-coding RNA in Cancer

Güngör Y., Gönül C. P., Şentürk Ş.

in: Cancer Immunology and Genetics: An Interdisciplinary Approach, Nima Rezaei, Editor, Springer, London/Berlin , London, pp.647-673, 2025

3. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue

Uluata Dayanç B., Eriş S., Şentürk Ş.

in: Lung Cancer Diagnosis and Treatment: An Interdisciplinary Approach, Rezaei Nima, Editor, Springer, Londrina, pp.217-247, 2024 Sustainable Development

Metrics

Publication

142

Publication (WoS)

Publication (Scopus)

Citation (WoS)

3729

H-Index (WoS)

Citation (Scopus)

3204

H-Index (Scopus)

Citation (Scholar)

10374

H-Index (Scholar)

Citation (Sobiad)

H-Index (Sobiad)

Total Citation Count

3768

Project

Intellectual Property

Thesis Advisory

Open Access

UN Sustainable Development Goals

Publications & Works

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)